Shopping Cart
Remove All
Your shopping cart is currently empty
Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $41 | In Stock | In Stock | |
| 10 mg | $57 | In Stock | In Stock | |
| 50 mg | $82 | In Stock | In Stock | |
| 100 mg | $124 | In Stock | In Stock | |
| 500 mg | $315 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $45 | In Stock | In Stock |
| Description | Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections. |
| Targets&IC50 | RdRP:341 nM. |
| In vitro | METHODS: RAW 264.7 cells were infected with MNV at an MOI of 0,001 using a T-705 dilution series (3.13-200 lg/mL). The MTS CPE reduction method was used to determine the antiviral activity of T-705 in the MNV/RAW 264.7 cell line. After 3 days of incubation, complete CPE was observed in the infected untreated cells. The cell culture supernatant was collected and analyzed by quantitative RT- PCR (qRT-PCR) quantitatively detects viral RNA load. RESULTS T-705 inhibited MNV-induced CPE (EC50: 39 ± 4 lg/mL [250 ± 11 lM]) and MNV RNA synthesis in cell culture (EC50: 19 ± 6 lg/mL [124 ± 42 lM]). [2] |
| In vivo | METHODS: When Favipiravir (T-705) is used at a dose of 1-100mg/kg and infected with a lethal dose of influenza virus A/Victoria/3/75 (H3N2), A/Osaka/5/70 (H3N2) or A/ Duck/MN/1525/81 (H5N1) was administered orally 2 or 4 times a day to mice for 5 days, and the survival rate of the mice was observed. RESULTS Favipiravir (T-705) showed improved survival compared with placebo at doses of 30 mg/kg/day or higher, the drug was also administered at doses of 33 mg/kg/day or higher Provides significant protection against A/Duck/MN/1525/81 (H5N1) virus. [1] METHODS: Favipiravir was administered at 120 mg/kg/day or 200 mg/kg/day on days 1-5 after lethal SFTSV infection in type I interferon receptor knockout (IFNAR −/−) mice. (T-705) and continued for 5 days to observe the growth status of the mice. RESULTS All favipiravir-treated mice at doses of 120 mg/kg/day or 200 mg/kg/day, respectively, survived lethal SFTSV infection when treatment was initiated within 3 and 4 days of infection. [3] |
| Cell Research | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
| Synonyms | T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide |
| Molecular Weight | 157.1 |
| Formula | C5H4FN3O2 |
| Cas No. | 259793-96-9 |
| Smiles | NC(=O)c1nc(F)cnc1O |
| Relative Density. | 1.78 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 12 mg/mL (76.38 mM), Sonication is recommended. H2O: 5 mg/mL (31.83 mM), Sonication is recommended. DMSO: 126 mg/mL (802.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (25.46 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||||||||||||
H2O/Ethanol/DMSO
Ethanol/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.